Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China
Yiqun Han(Mayo Clinic), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Zongbi Yi(Wuhan University), Pei Yu(Shanghai Jiao Tong University), Huawei Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Min Yan(Zhengzhou University), Li Cai(Wenzhou Medical University), Tao Sun(Wuhan University), Xiaojia Wang(Henan University of Science and Technology), Xinlan Liu(Yunnan Agricultural University), Tao Huang(Union Hospital), Yuee Teng(First Hospital of China Medical University), Yongmei Yin(Nanjing Medical University), Jin‐Hu Fan(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Shun-e(Xinjiang Medical University), Shusen Wang(Sun Yat-sen University), Hui Li(Sichuan Cancer Hospital), Hongyuan Li(Central South University), Runxiang Yang(Kunming Medical University), Jiayu Wang(Chongqing Medical University), Wenna Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Quchang Ouyang(Hunan Cancer Hospital), Jianjun He(Hebei Medical University), Xichun Hu(Fudan University Shanghai Cancer Center), Zhongsheng Tong(Institute of Oncology NN Petrov), You‐Lin Qiao(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 7
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide
|International Journal of Cancer|2006|417
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
|Signal Transduction and Targeted Therapy|2019|406